Memantine and Cognitive Dysfunction in Bipolar Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Bipolar Disorder
Interventions
DRUG

Memantine

Week 0: 5 mg memantine or placebo once a day (q.d.) Week 1: 5 mg memantine or placebo twice a day (b.i.d.) Week 2-3: 5 mg memantine or placebo once in the morning (q.a.m.)/10 mg once in the evening (q.p.m.) Week 4-12: 10mg Memantine or placebo b.i.d.

DRUG

Placebo

Inactive comparator. Placebo-matching memantine tablet.

Trial Locations (3)

60611

Asher Depression Center, Northwestern University, Chicago

90048

Cedars Sinai Department of Psychiatry, Los Angeles

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Forest Laboratories

INDUSTRY

lead

Massachusetts General Hospital

OTHER